Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Summary:
- Price Zscore is at a recent 2 week low. A recent low ZScore means price drop is accelerating at a record speed.
- Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.
| MarketCap | 694.5M |
|---|---|
| PE Ratio | |
| PEG Ratio | 1.7 |
| P/B | 16.2 |
| P/S (ttm) | 20.4 |
| Earning Growth (QoQ) | |
| Revenue Growth (QoQ) | |
| Short % | 6% |
| Held by Institutions % | 66% |
| 1 Day Vol Adjusted Return | -2.4 |
| 1 Month Vol Adjusted Return | -0.5 |
| 3 Month Vol Adjusted Return | 17.3 |
| 6 Month Vol Adjusted Return | 29.9 |
| 20 Days SMA Price ZScore | -2.6 |
| 50 Days SMA Price ZScore | 0.0 |
| 12 -26 Days PPO | 3.9 |
| 1 Month Average Short Volume Ratio | 47.2 |
| 1 Day Volume Change ZScore | 1.6 |
| 1 Month Daily Vol | 6.2 |
Stock news
ROCHESTER, Mich., March 03, 2021 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, has been invited to present at the 33rd Annual ROTH Growth Conference being held virtually on March 15-17, 2021. The conference will feature presentations from public and private companies across a variety of industry sectors, followed by one-on-one and small group meetings, as well as expert panels and fireside ...
OptimizeRx Corp. (OPRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
OptimizeRx is disrupting the pharmaceutical sales call with an internet option for marketing drugs to doctors.
Moderna, Teladoc Health, and Fulgent Genetics have all spiked a lot higher because of COVID-19. And all three companies have platforms for growth over the next decade.
OPRX earnings call for the period ending December 31, 2020.
ROCHESTER, Mich., Feb. 24, 2021 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, reported results for the fourth quarter and full year ended December 31, 2020. Quarterly and full year comparisons are to the same year-ago period. Financial Highlights Revenue in the fourth quarter of 2020 increased 123% to a record $16.4 million, with the full year of 2020 up 76% to a record $43.3 million.Gross ...
NEW YORK, NY / ACCESSWIRE / February 24, 2021 / OptimizeRx Corp. (NASDAQ:OPRX) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on February 24, 2021 at 4:30 PM Eastern Time.
List Celebrates Accomplished Young Talent in Medical MarketingROCHESTER, Mich., Feb. 23, 2021 (GLOBE NEWSWIRE) -- OptimizeRx Corporation (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, announced its senior vice president and principal of agency channels, Angelo Campano, has been named to MM+M’s 2021 ‘40 Under 40’ list for his accomplishments and contributions to the healthcare marketing industry. The 40 Under 40 list shines a li...